According to the Congressional Budget Office (CBO), enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The Congressional Budget Office (CBO) has released its score of the Senate Committee on Health, Education, Labor, and Pensions’ proposed bill, S.1895, the Lower Health Care Costs Act. According to the CBO, enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The proposed legislation comprises 5 elements: ending surprise medical bills, reducing the prices of prescription drugs, improving transparency in health care, improving public health, and improving the exchange of health information.
Among those sections, elements aimed at reducing drug prices would be responsible for a substantial share of the savings; the CBO says that these provisions would result in a net decrease in the deficit of $4.6 billion over the coming decade.
Key to reducing drug prices are several of the bill’s provisions that apply to generics and biosimilars. According to the CBO, some of these elements of the bill would allow generics and biosimilars to reach the market sooner, leading to a decline in federal spending on prescription drugs and subsidies for health insurance.
Provisions in this portion of the bill would allow the FDA to:
The CBO states that the section of the bill providing the right to sue over sample availability and removal of the requirement to share a risk management system would, on its own, account for more than $3.7 billion in savings over 10 years. This substantial reduction in the deficit would result, in part, from the ability of generics and biosimilars to reach the market 1 to 2 years earlier, on average.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.